Fixed-dose combination treatment regimen to control intraocular pressure in glaucoma
<p> <b>V.N. Alekseev<sup>1</sup>, I.R. Gazizova<sup>2</sup>, A.M. Gadzhiev<sup>3</sup></b><br> </p> <p> <b><sup>1</sup>I.I. Mechnikov North-Western State Medical University...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Prime-Media
2019-11-01
|
| Series: | РМЖ "Клиническая офтальмология" |
| Online Access: | http://clinopht.com/upload/iblock/7c5/7c57e0d6c78466a65e68d7abbf0e7c90.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <p>
<b>V.N. Alekseev<sup>1</sup>, I.R. Gazizova<sup>2</sup>, A.M. Gadzhiev<sup>3</sup></b><br>
</p>
<p>
<b><sup>1</sup>I.I. Mechnikov North-Western State Medical University, St. Petersburg, Russian Federation</b>
</p>
<p>
<b><sup>2</sup>Institute of Experimental Medicine, St. Petersburg, Russian Federation</b>
</p>
<p>
<b><sup>3</sup>Vsevolozhsk Clinical Inter-district Hospital, Vsevolozhsk, Russian Federation</b>
</p>
<p>
<br>
</p>
<p>
<i><b>Aim</b>: to assess the efficacy and safety of the treatment with fixed-dose (FDC) and non-fixed-dose combination of latanoprost 0.005% and timolol 0.5% when switching from monotherapy to enhance IOP-lowering effect in primary open-angle glaucoma (POAG).</i>
</p>
<p>
<i><b>Patients and Methods:</b> 54 patients (93 eyes) with POAG were enrolled in this 4-week study. All patients were subdivided into three groups depending on the treatment regimen. In group I, latanoprost/timolol FDC dosed in the morning (8 A.M.) was prescribed. In group II, latanoprost/timolol FDC dosed in the evening (8 P.M.) was prescribed. In group III, non-FDC of latanoprost 0.005% dosed in the evening (8 P.M.) and timolol 0.5% dosed in the morning (8 A.M.) and in the evening (8 P.M., 15-minute interval to prevent latanoprost from being washed out by timolol) was prescribed.</i>
</p>
<p>
<i><b>Results</b>: by the end of week 4, in group I, IOP has reduced by 4.2 mm Hg (16.8% from the baseline) when measured at 10 A.M. and by 4.1 mm Hg (16.6% from the baseline) when measured at 4 P.M. In group II, IOP has reduced by 4.6 mm Hg (19.1% from the baseline) when measured at 10 A.M. and by 4.4 mm Hg (18.6% from the baseline) when measured at 4 P.M.</i><i>caIn group III, IOP has reduced by 3.2 mm Hg (13.6% from the baseline) when measured at 10 A.M. and by 3.3 mm Hg (14.1% from the baseline) when measured at 4 P.M. Interviewing on medication adherence has demonstrated that the average percentage of eye drops taken in time was 63.4% from the required that is lower by 12.7% and 12.2% than in group I and group II, respectively.</i>
</p>
<p>
<i><b>Conclusion</b>: combination of latanoprost and timolol provides additional IOP lowering in all three groups. Morning instillation of FDC provides additional IOP lowering by 3.2% and 2.5% when measured at 10 A.M. and 4 P.M., respectively, as compared with group III. Evening instillations of FDC provide additional IOP lowering by 5.5% and 4.5% when measured at 10 A.M. and 4 P.M., respectively, as compared with group III. Evening instillations are more beneficial due to the effect on diurnal IOP fluctuations. Our findings demonstrate low rate of adverse side effects.</i>
</p>
<p>
<i><b>Keywords</b>: glaucoma, POAG, intraocular pressure, fixed-dose combination, prostaglandin analogues, latanoprost, beta-blocker, timolol, Xalacom.</i>
</p>
<p>
<i><b>For citation:</b> Alekseev V.N., Gazizova I.R., Gadzhiev A.M. Fixed-dose combination treatment regimen to control intraocular pressure in glaucoma. Russian Journal of Clinical Ophthalmology. 2019;19(4):202–205.</i>
</p>
<i><br>
</i><br> |
|---|---|
| ISSN: | 2311-7729 2619-1571 |